ABSTRACT. Glucose production and oxidation were measured in ventilated preterm appropriate-for-gestational-age and small-for-gestational-age infants on the first day of life. Using a new technique of NaH13C03 infusion followed by a [U-"C]glucose infusion, we measured glucose oxidation rates without measuring the COz production rate. Infants were studied at 18 f 4 h (mean f 1 SD) of life and received parenterally administered glucose only (4.2 f 0.5 m g kg-'. min-I). In 13 of 16 patients, the glucose production rate exceeded 1.0 mg. kga'.min-'. Infants born from mothers who had been receiving steroids antenatally had higher glucose production rates (2.3 f 1.1 m g kg-'. min-') compared with infants from mothers who had not (1.1 2 0.8 mg . kg-'. min-', p = 0.036). The glucose oxidized (2.9 f 1.0 mg. kg-'.min-') was lower than the amount of glucose infused ( p = 0.005) and was not different for appropriate-for-gestational-age and small-for-gestationalage infants. Plasma levels of glucose, insulin, glucagon, and total IGF-I were not correlated with glucose metabolism on the first day of life. Total IGF-I1 levels were negatively correlated with the rate of glucose appearance. We conclude that preterm infants on the first day of life receiving a glucose infusion of 4.2 mg kg-'. min-' continue to produce glucose. The glucose oxidation rate is lower than the glucose infusion rate and the contribution of glucose oxidation to the total energy expenditure is limited. (Pediatr Res 33: 583-589,1993) Abbreviations Ra, rate of appearance GPR, glucose production rate AGA, appropriate for gestational age SGA, small for gestational age [U-'3Cjglucose, uniformly I3C-labeled glucose
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The fetus in utero relies on glucose as the main source of energy. Glucose is obtained from the mother by rapid flow through the placenta (1, 2) . After birth, a shift from glucose as the major energy source to a carbohydrate-fat mixture as the energy source is observed in term infants (3, 4) . Whether this rearrangement of metabolic fuels directly after birth also takes place in preterm infants is not known, but very-low-birth-weight infants often require a continuous glucose infusion to prevent hypoglycemia. However, even with a glucose infusion, these infants are prone to disturbances in glucose homeostasis during the first few days of life (5) . This might be due to a limited gluconeogenesis or a glucose utilization at the same high level as in utero. Thus, to understand the disturbances in glucose level, the GPR as well as the glucose oxidation rate and the nonoxidative disposal rate have to be known.
Several studies of glucose kinetics have been performed in 1-to 2-d-old neonates (6-1 I), but only in the study camed out by Denne and Kalhan (7) was glucose oxidation measured. The oxidation rate of fasted term infants appeared to be more than twice that in adults. No data have been published on the glucose oxidation of preterm infants directly after birth while receiving a continuous glucose infusion.
The aim of the present study was to assess the importance of glucose oxidation regarding energy metabolism in ventilated SGA and AGA preterm infants receiving a continuous infusion of glucose on the first day of life. The glucose production was measured by the stable isotope dilution technique. Serum levels of hormones involved in glucose metabolism were measured as well.
SUBJECTS AND METHODS
Patients. Ten AGA and six SGA preterm infants (1 1 male, five female) were included in the study. SGA infants were defined as infants with a birth weight more than 2 SD below the mean birth weight for gestation, whereas AGA infants had a birth weight between -2 and +2 SD according to the charts of Usher and McLean (12). Gestational age was determined by maternal history and Ballard score (13).
The following criteria were met by all infants studied: birth weight less than 2 kg, artificial ventilation or continuous positive airway pressure through an endotracheal tube, venous and arterial catheter placed for clinical reasons, no congenital abnormalities, and no infusion of erythrocytes or plasma before the study.
The clinical characteristics of the infants are described in able I. The infants were studied between 12 and 26 h after birth and were kept in a thermoneutral environment throughout the study. All infants received a 10% (wt/vol) glucose infusion at 60 mL. kg-'.d-', starting within 1 h after birth, except for one SGA infant who received a 5% (wt/vol) glucose infusion because of hyverdycemia directly after birth. The ducose infusion rate was cillin and cefotaxime), although no positive blood cultures were found in any of the infants. P-Sympathomimetic drugs had been given to nine mothers to inhibit uterine contractions. Several studies have shown an effect of these drugs on glucose metabolism ( 14-16). Corticosteroids (betamethasone) had been given to five mothers to accelerate fetal lung maturation (Table I ). The use of stable isotopes for human investigations had been approved by the ethical committee of the Erasmus University Rotterdam. Informed consent for the study was obtained from at least one of the parents.
Methods. All infants had an endotracheal tube placed and were scored according to an adapted ventilatory scoring system (17). This ventilatory scoring system uses the concentration of oxygen in the inspiratory air (Fi02), the mean airway pressure (MAP), and ventilatory frequency (VF) according to the following formula:
where VS is the ventilatory score.
Isotope infusion. 13C-labeled sodium bicarbonate (NaHi3C03) (99% enriched, Isotech, Miamisburg, OH) and uniformly labeled glucose (I3C6Hl2O6) (98.7% enriched, Isotech) were diluted in 0.9% NaCl by the hospital pharmacy and filtered through a 0.22-pm Millipore filter into sterile vials.
A priming dose of 6.9 pmol NaHI3CO3/kg was followed by a continuous infusion of 4.7 pmol. kg-'. h-' (18). This infusion lasted for 2 h. After this period, an additional priming dose (10.4 pmol/kg) was given to prime the bicarbonate pool before the labeled glucose was infused. The NaHL3C03 enrichment of the solution was confirmed by conversion to I3CO2 on an isotope ratio mass spectrometer (SIRA 10, VG Isotech Ltd., Middlewich, Cheshire, UK). After the labeled bicarbonate infusion was stopped, a primed continuous infusion of [U-'3C]glucose was started. A priming dose of 8.7 pmol/kg was followed by a continuous dose of 4.8 pmol. kg-' .K1. The infusion of the labeled glucose lasted for 5 h. Tracers were given using a Harvard infusion pump (M22, Harvard Apparatus Co. Inc., S. Natick, MA) and administered via the same infusion route as the unlabeled glucose.
Arterial blood samples were drawn before the infusion of the stable isotopes, at 30 min before the end, and at the end of the [U-'3C]glucose infusion.
Measurement of isotope dilution in plasma. Methanol (500 pL) was added to 100 pL of plasma to precipitate plasma proteins.
,up averages are presented as mean f 1 SD.
The supernatant was evaporated under nitrogen to dryness. One hundred fifty pL 1.2% (vol/vol) butyl boronic acid dissolved in pyridine was added to the dried glucose containing residue and heated at 95°C for 30 min. The tubes were allowed to cool. Acetylation was carried out by adding 50 pL acetic anhydride and leaving the tubes at room temperature for 30 min. The derivative was washed by adding 1 mL of hexane and I ml, of 0.1 N hydrochloric acid. The hexane layer was transferred to a clean test tube, evaporated to dryness, and reconstituted with 100 pL of hexane.
Gas chromatography/mass spectrometry was camed out on a Hewlett-Packard (Palo Alto, CA) HP 5988A mass spectrometer coupled to an HP 5890 Series I1 gas chromatograph. Chromatography was carried out on a Durabond (Folsom, CA) DB 130 1 fused silica capillary column. The column had a length of 30 m, an internal diameter of 0.25 mm, and a film thickness of 0.25 pm. Selective ion monitoring was camed out at m/z 297.2 and m/z 303.2 for (m) and (m+6) enrichment, respectively. The plasma glucose enrichments were determined using a calibration graph constructed from standard mixtures ranging from 0 to 0.35% [U-13C]glucose. The coefficient of variation for plasma glucose measurements in triplicate ranged from 0.8 to 4.8%. The plateau glucose enrichments were calculated as percent enrichments above the baseline enrichments.
Glucose oxidation measurement. Expiratory C 0 2 was collected at the outlet of the ventilator. Air leaving the ventilator was led through an all-glass spiral filled with freshly prepared NaOH (1.0 N).
Six baseline expiratory air samples were taken to determine the natural abundance of I3CO2. One h after the primed NaHi3C03 infusion started, 5-min CO2 collections were performed at 10-min intervals for I h. After the [U-13C]glucose was started, C02 collections were made at hourly intervals for the first 3 h, at 30-min intervals for the fourth hour, and at 10-to 15-min intervals for the final hour. Breath samples were analyzed for enrichment of 13C02, as described earlier (19).
Plasma analyses. Arterial blood samples were put directly on melting ice and centrifuged at 4°C. Plasma was divided into aliquots and stored at -80°C. The whole procedure did not exceed 15 min.
Insulin and glucagon were measured (Laboratory of Endocrinology, IJsselland Ziekenhuis, Capelle a/d IJssel, The Netherlands) by an RIA in 350 pL of plasma obtained at the end of the study. Blood was collected in heparinized tubes. Sensitivity of the assay was better than 15 pmol/L for insulin and 2.9 pmol/L for glucagon. Plasma IGF-I and IGF-I1 were measured in 100 pL of plasma after acidification with 0.5 mol/L HCL and 5 mmol/L CaC12 and extracted using C18 Sep-Pak cartridges (Waters, Millipore, Milford, MA). This method effectively removes interfering binding proteins from serum. IGF levels were measured with an antiserum (IGF-I) and an MAb (IGF-11) RIA (Laboratory of Endocrinology, Wilhelmina Children's Hospital, Utrecht, The Netherlands) (20).
Glucose concentration was analyzed in a Cobas Mira (Roche, Basel, Switzerland), according to the glucose-oxidase N-(4-antipyri1)-p-benzochinonimin method from Merck (Darmstadt, Germany). Blood was also obtained to measure FFA. In 100 pL of serum, an enzymatic colorimetric test was performed (NEFAC, Wako Chemicals GmbH, Neuss 1, Germany).
Calculations. Turnover of glucose was calculated by dividing the tracer infusion by the mean of the two plasma measurements of the plateau of the [U-'3C]glucose enrichment (Appendix, equation I). The GPR was calculated by subtracting the rate of glucose infusion from the rate of glucose appearance (Appendix, equation 2).
Glucose oxidation (Appendix, equations 3-5) was determined assuming that the C 0 2 production during the NaH13C03 infusion was equal to the C 0 2 production during the [U-'3C]glucose infusion. By determining the increase in I3CO2 enrichment of each individual patient during both the NaHI3CO3 infusion and the [U-'3C]glucose infusion, variance can be diminished and there is no need for measuring the rate of COz excretion (2 1).
Results are presented as mean + 1 SD or in cases of apparent skewness as median with the interquartile ranges between brackets. The Mann-Whitney U test and the Wilcoxon signed-rank test were used for comparison between independent and paired data, respectively. calculations. Plateau enrichment was determined visually and incidentally confirmed by exponential curve fitting.
Glucose production, glucose oxidation, and nonoxidative glucose disposal rates for individual patients are shown in Table 2 .
In 13 of 16 patients, the GPR was >I .O mg . kg-' . min-' while they were receiving a continuous glucose infusion of 4.2 + 0.5 m g kg-'. min-I. Although the glucose production was lower in SGA infants, the difference did not reach significance ( p = 0.051). We found the GPR to be twice as high in infants (four AGA and one SGA) from mothers who had received steroids compared with the infants not exposed to corticosteroids (2.28 a 1.05 mg. kg-' . min-' versus 1.13 f 0.80 mg. kg-' . min-', p = 0.036). Comparing these two groups on clinical variables, we could not find any differences. The oxidation rate was found to be lower than the glucose infusion rate in both groups of infants ( p = 0.0052). We did not observe any difference in glucose oxidation between AGA and SGA infants ( p = 0.78).
The total Ra was correlated with head circumference ( r = 0.58, p = 0.02). Head circumference, however, was not correlated with total glucose oxidation (r = 0.06), nor was the head circumference to body weight ratio (r = -0.16).
The ventilatory status and the infant's condition just after birth, reflected by the Apgar score at 5 min, were not related to the glucose kinetics. We were also unable to show any effect of the antenatally administered (3-sympaticomimetics.
The median insulin level in the AGA infants was 3 1.5 (22-87) pmol/L compared with 22.4 (22-28) pmol/L in the SGA infants ( p = 0.19). No correlation could be seen with GPR (Fig. 3) . Glucagon levels, which were only measured in five patients in each group, were lower in AGA infants (Fig. 4) . 
DISCUSSION
Approximately 50% of plasma glucose was oxidized in our group of 1-d-old preterm infants (range, 27 to 82%). In preterm infants 7 to 28 d old, the percentage of the glucose rate of disappearance used for oxidation is higher (>60%) (19). The data shown in the present article match very well with data obtained from studies in fetal lambs and term infants. Fetal glucose utilization rate measured in lambs was 4.7 m g kg-'. min-', with a glucose oxidation rate of 2.5 mg . kg-' . min-' (22). In 1 1 fasted human newborns, Denne and Kalhan (7) measured a glucose oxidation rate of 2.53 mg. kgW1.min-', which represented 53% of the glucose turnover.
We found that the amount of glucose oxidized is less than the amount of glucose infused in 11 of 14 patients. The amount of calories provided by glucose oxidation is far less than the total energy expenditure measured recently by Hazan et al. (23). They found a metabolic rate of 40 to 50 kcal. kg-' . d-' in ventilated infants, measured shortly after birth. On average, the oxidation of glucose in our study population produced less than 17 kcal. kg-' .d-' and thus fell short of satisfying the energy expenditure. in full-term, 1-d-old neonates (24). Using [l-'3C]palmitic acid as a tracer, they found FFA fluxes comparable to fluxes in fasted adults. By assuming an oxidation rate of 30%, the energy obtained by fat oxidation was estimated to be 11 to 13.5 kcal. kg-'. d-'. From indirect calorimetry studies, however, Pate1 and Kalhan (25) recently reported the oxidation rate of fatty acids in fasted AGA term infants to be equivalent to 25 kcal . kg-'. d-' and in SGA infants to be 30 kcal. kg-' . d-'. The latter data are much more in agreement with our findings, giving the following energy partition: 35-40% is delivered by glucose oxidation, 50-60% by fatty acid oxidation, and the remaining energy needed could be derived from protein oxidation. Studies on fatty acid oxidation and amino acid oxidation have to be performed in preterm infants to confirm this picture of energy partition. The nonoxidative disposal rate was approximately 3 mg. kg-'.
min-I. A large part, 2 mg.kg-'.min-', can be explained by glucose being shuttled into different pathways, for instance the pentose phosphate cycle. A simultaneous release of glucose coming from these pathways will result in a GPR of 2 mg . kg-'. d-I. Other glucose molecules might be used as carbon skeleton for amino acids. Lipogenesis as a major route of nonoxidative disposal might be important in patients who are in an anabolic state and receive enough glucose and calories. The infants in the present study were in a catabolic state, with low insulin levels, and received a low energy intake. Although lipogenesis may still take place under these circumstances, it is not likely that this pathway is an important route of carbon disposal. Finally, some glucose might be stored as glycogen. The present study does not allow us to distinguish between these different routes of carbon disposal.
Complete suppression of GPR is found in adults at an intake of 4 m g kg-'. min-' or higher (26) but not in preterm infants as shown in this study and in other studies (6, 8, 10, 11, 27) . The large differences found in the rate of glucose appearance (range 4.2-7.2 mg. kg-'. min-') in neonates might be explained by the different tracers used (8) . With Glucose recycling has been measured in neonates and ranged from 3 to 20% of the Ra when two different tracers, [6,6-2H2] glucose and [l-'3C])glucose, were used (8) . Using [U-'3C]glucose and determining the difference of the m+6 and the m+ 1 enrichment a value of 36% has been found (7). We measured the glucose oxidation by multiplying the rate of disappearance with the recovery of the label in expiratory air. We used the m+6 enrichment to calculate the rate of glucose disappearance, but oxidation of glucose molecules with one to five I3C-atoms will also result in labeled C 0 2 in expiratory air. The glucose oxidation found in this study could thus be an overestimation, emphasizing even more the relatively small contribution of glucose oxidation to the energy demand of preterm infants on the first postnatal day.
This study shows that antenatal steroid administration increases the GPR. Many corticosteroids like betamethasone have a gluconeogenetic effect that is more potent than the effect of prednisone. The drug administered to the mother still seems to exert an effect 18 h after birth in these infants. Whether there is a long-term effect of these drugs is not known, but the potential effect should be considered when interpreting glucose kinetics in preterm neonates.
Glucose is believed to be the main energy substrate for the brain (5) . Bier et al. (27) found a linear relationship between GPR in fasted preterm infants and estimated brain weight. We measured head circumference and found no correlation with glucose oxidation. Also, asymmetric infants, i.e. infants with a high head circumference to body weight ratio, did not oxidize more glucose. Glucose might still be the main substrate as an energy source, but our data do not support the hypothesis that the brain is the main site of glucose oxidation. Ketone bodies, glycerol, and lactate might also play significant roles as energy sources for the brain (28).
The role played by the major glucoregulatory hormones in adults, insulin and glucagon, in controlling the glucose homeostasis in the preterm infant is not yet clear (29). Susa et al. (30) found a suppression of GPR by insulin infusion in newborn lambs. No effect of insulin and glucose infusions on glucagon levels was found. In our study, we found no correlation between insulin levels measured at the end of the study and any of the glucose kinetic parameters. Also, the level of glucagon was not correlated with the GPR.
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Insulin might also exert an effect via IGF. IGF levels are increasing from wk 22 of gestation onward, which might be an indicator of some importance regarding the metabolic effects of these factors around birth (31, 32). IGF-I infusion has been shown to increase glucose uptake and to inhibit hepatic glucose production in healthy adults and in rats (33-35). It has been shown in normal rats that the effects of IGF-I and insulin on glucose metabolism are identical and additive (36) . Insulin itself is said to promote IGF-I production (37), although in this study we could not find a correlation with IGF-I. We did find a negative correlation between IGF-I and FFA levels, indicating a inhibitory effect of IGF-I on lipolysis. IGF-I levels, similar to insulin levels, were not correlated with glucose metabolism.
Surprisingly, we found a negative correlation between IGF-I1 and the rate of glucose appearance. The potency and working mechanism of IGF-I1 regarding glucose metabolism is unclear, but usually IGF-I1 is said to be a less potent glucoregulatory hormone than IGF-I. In fasted lambs, IGF-I1 infusion led to a small increase in glucose uptake (1 5 %), whereas IGF-I increased glucose clearance by 55% (35) . In contrast to insulin, both IGF-I and IGF-I1 failed to suppress glucose production in that study. Plasma IGF-I1 levels were not measured, and IGF-I showed an effect only at levels of 240 g / L (31.4 pmol/L) and not at 67 pg/L (8.8 pmol/L). The levels found for IGF-I and IGF-I1 in our study are lower than those reported by Lassarre et al. (3 1) found in cord blood in utero. We found no differences between levels in growth-retarded and AGA infants.
It may well be that, in spite of relatively stable plasma glucose levels, a relatively long time is needed to stabilize the hormones involved in glucose metabolism after the stressful event of birth. Active intervention by an infusion of recombinant human IGF or insulin could have given different results.
In conclusion, we observed that the contribution of the glucose oxidation to the energy demand is relatively small on the first day of life in preterm infants. It is not yet clear to what extent the oxidation of other substrates contributes to the energy demand. Insulin, glucagon, or IGF-I levels, measured once as in this study, are not related to glucose metabolism in preterm infants during the first day of life. and I(B) is the NaHI3CO3 infusion rate in pmol . kg-' . min-'.
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